MedTrace Logo

Behavioral Effects of Kuvan in Children With Mild Phenylketonuria

NCT00827762 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2013-12-05

No results posted yet for this study

Summary

The purpose of this study is to determine whether improvements in behavior occur in children with phenylketonuria (PKU) who are taking Kuvan.

Conditions

Interventions

DRUG

Kuvan

20/mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.

Sponsors & Collaborators

  • BioMarin Pharmaceutical

    collaborator INDUSTRY

  • University of Missouri-Columbia

    collaborator OTHER

  • Northwestern University

    collaborator OTHER

  • Oregon Health and Science University

    collaborator OTHER

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Desiree White, Ph.D. · Washington University School of Medicine

  • Dorothy K. Grange, M.D. · Washington University School of Medicine

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00827762 on ClinicalTrials.gov